Introduction to the GHIAA MAPGuide

Julie Barnes-Weise, JD, CLP
Executive Director, GHIAA

https://ghiaa.org/mapguide-home/
Overview

What is it?
The MAPGuide® is an open access tool for users to access & explore **analysis of provisions from global health agreements**.

It is organized into “issues” which are key areas of consideration for developing and rapidly concluding global health agreements with the aim of enabling increased global access to medical products.

Why did we develop it?
The 2014 Ebola outbreak in West Africa exposed significant gaps in pandemic preparedness, and the resources available to support response.

**Agreements are an important tool in pandemic response** because they create enforceable obligations for the development and supply of medical products. Transparency and knowledge of how those terms are included in agreements is essential to accelerating access.
MAPGuide Issues

**Equitable Access**
How do you ensure products are accessible & affordable to those in need?

**Protecting & Sharing Information**
What information must be shared confidentially? What must be made public?

**Intellectual Property**
Who owns the intellectual property? Who can use it and for what?

**Term & Termination**
Who can end the agreement and when? What happens when it ends?

**Liability**
Who is legally & financially responsible if something goes wrong?

**Business Model**
Who pays for what? How are key decisions made?

More detailed explanations are available at: [https://ghiaa.org/mapguide-home/#issueintro](https://ghiaa.org/mapguide-home/#issueintro)
Search Options (1)

- By Issue
- By Agreement Feature - technology, development stage, partner type, agreement type
- Advanced Search - combination of issue & agreement feature
Search Options (2)

- **All Agreements** - [full list of agreements](#) and related provisions
- **Quick search** - type a keyword (e.g. COVID-19) into the search bar on the home page

### All Agreements

<table>
<thead>
<tr>
<th>Agreement Title</th>
<th>Effective date</th>
<th>Partner type</th>
<th>Technology</th>
<th>Development stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Academic Institution - Company Research Collaboration Agreement</td>
<td>2016</td>
<td>Academic Institution</td>
<td>Vaccine</td>
<td>Discovery Concept Preclinical Early clinical (Phase 2) Late clinical (Phase 3) Commercialization Field Testing</td>
</tr>
<tr>
<td>ASTM Model Inter-Institutional Research Collaboration Agreement</td>
<td>2015</td>
<td>Academic Institution</td>
<td>Drug</td>
<td>Vaccine</td>
</tr>
<tr>
<td>ASTM Preliminary Patent Management Agreement</td>
<td>2013</td>
<td>Academic Institution</td>
<td>Drug</td>
<td>Vaccine</td>
</tr>
<tr>
<td>BARDA - Moderna, COVID-19 Vaccine Development Agreement</td>
<td>2020</td>
<td>Government</td>
<td>Industry</td>
<td>Vaccine</td>
</tr>
</tbody>
</table>

### Search Results For: COVID-19

<table>
<thead>
<tr>
<th>Agreement Title</th>
<th>Effective date</th>
<th>Partner type</th>
<th>Technology</th>
<th>Development stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>European Commission - Eucerin, COVID-19 Vaccine Advance Purchase Agreement</td>
<td>2020</td>
<td>Biotechnology company</td>
<td>Vaccine</td>
<td>Late clinical (Phase 3) Commercialization</td>
</tr>
<tr>
<td>European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement</td>
<td>2020</td>
<td>Government</td>
<td>Multinational pharmaceutical company</td>
<td>Vaccine</td>
</tr>
<tr>
<td>UK Secretary of State - AstraZeneca, COVID-19 Vaccine Supply Agreement</td>
<td>2020</td>
<td>Government</td>
<td>Multinational pharmaceutical company</td>
<td>Vaccine</td>
</tr>
<tr>
<td>US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement</td>
<td>2020</td>
<td>Biotechnology company</td>
<td>Vaccine</td>
<td>Preclinical Early clinical (Phase 2) Late clinical (Phase 3)</td>
</tr>
<tr>
<td>Spain - Translating this, influenza and COVID-19 Vaccine Collaboration &amp; License Agreement</td>
<td>2020</td>
<td>Biotechnology company</td>
<td>Multinational pharmaceutical company</td>
<td>Vaccine</td>
</tr>
</tbody>
</table>

---

[MAPGuide Home](#) | [Browse Provisions](#) | [All Agreements](#) | [Resources & Analysis](#)
Limitations & Future Additions

• The MAPGuide should **not** be viewed as a ‘complete’ or ‘final’ data set.
  ○ We have a backlog of agreements to be analyzed and are continuously searching for new agreements.
  ○ There are many agreements that organizations are not required or willing to make publicly available.

• We encourage all organizations, whether public, private, academic or non-profit, to contribute agreements. We accept redacted & anonymized agreements, as well as extracts of relevant provisions. Contact [comms@ghiaa.org](mailto:comms@ghiaa.org).

• We are building a collection of [Commentaries](#) to explain and compare approaches to key issues based on provisions in the MAPGuide.®
Appendix: Reviewing MAPGuide Search Results

https://ghiaa.org/mapguide-home/
**MAPGuide: Search Results**

- **Results screen** - list of all agreements with a provision relevant to your search criteria. Click the + icon to view the list of provisions, then click a link to view an individual provision.

- **Provision** - divided into Context, Structural Questions, Summary of Approaches, Annotation, Provision Language, pop-up definitions.
MAPGuide: Provisions

• **Context:** background information about the agreement.

• **Provision Language:** extract from the agreement section(s) relevant for the issue.

• **Structural Questions:** questions to consider when creating an agreement provision to address the issue.

• **Summary of Approaches:** overview of the approach taken to the issue & structural questions addressed in this agreement.

• **Annotations:** summary of the purpose of the agreement and any items of note.

• **Download Full Agreement:** for a PDF copy of the complete document.